Mochida Pharmaceutical Co., Ltd. (TYO:4534)
3,730.00
-15.00 (-0.40%)
Feb 13, 2026, 3:30 PM JST
Mochida Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | 38,502 | 45,154 | 33,290 | 47,010 | 48,415 | 54,487 |
Short-Term Investments | 2,995 | 5,996 | 13,499 | 13,499 | 13,499 | 8,999 |
Cash & Short-Term Investments | 41,497 | 51,150 | 46,789 | 60,509 | 61,914 | 63,486 |
Cash Growth | -22.55% | 9.32% | -22.67% | -2.27% | -2.48% | 3.58% |
Receivables | 40,202 | 31,617 | 34,838 | 27,806 | 31,676 | 29,189 |
Inventory | 34,916 | 33,295 | 30,278 | 24,404 | 23,127 | 22,605 |
Other Current Assets | 3,875 | 3,607 | 4,757 | 4,660 | 4,731 | 3,513 |
Total Current Assets | 120,490 | 119,669 | 116,662 | 117,379 | 121,448 | 118,793 |
Property, Plant & Equipment | 16,109 | 15,940 | 15,874 | 15,049 | 14,528 | 13,299 |
Long-Term Investments | 37,663 | 21,740 | 23,169 | 21,722 | 22,758 | 25,853 |
Other Intangible Assets | 1,196 | 920 | 721 | 797 | 713 | 646 |
Long-Term Deferred Tax Assets | 883 | 1,851 | 2,372 | 3,883 | 3,691 | 3,198 |
Other Long-Term Assets | 5,879 | 1 | 2 | 1 | 1 | 2 |
Total Assets | 182,220 | 160,121 | 158,800 | 158,831 | 163,139 | 161,791 |
Accounts Payable | 13,907 | 8,660 | 12,182 | 9,957 | 11,899 | 9,722 |
Accrued Expenses | 1,289 | 2,357 | 2,178 | 2,374 | 2,711 | 2,536 |
Current Income Taxes Payable | 1,197 | 1,510 | 593 | 501 | 1,652 | 2,061 |
Other Current Liabilities | 13,635 | 12,375 | 11,120 | 14,426 | 13,594 | 14,391 |
Total Current Liabilities | 30,028 | 24,902 | 26,073 | 27,258 | 29,856 | 28,710 |
Pension & Post-Retirement Benefits | 3,539 | 3,690 | 3,908 | 4,133 | 4,270 | 4,652 |
Other Long-Term Liabilities | 822 | 835 | 853 | 666 | 367 | 1,455 |
Total Liabilities | 44,790 | 29,427 | 30,834 | 32,057 | 34,493 | 34,817 |
Common Stock | 7,229 | 7,229 | 7,229 | 7,229 | 7,229 | 7,229 |
Additional Paid-In Capital | 1,871 | 1,871 | 1,871 | 1,871 | 1,871 | 1,871 |
Retained Earnings | 119,620 | 116,114 | 117,022 | 118,943 | 121,668 | 116,288 |
Treasury Stock | -3,269 | -3,267 | -7,021 | -7,114 | -9,617 | -8,857 |
Comprehensive Income & Other | 11,979 | 8,747 | 8,865 | 5,845 | 7,495 | 10,443 |
Shareholders' Equity | 137,430 | 130,694 | 127,966 | 126,774 | 128,646 | 126,974 |
Total Liabilities & Equity | 182,220 | 160,121 | 158,800 | 158,831 | 163,139 | 161,791 |
Total Debt | 10,000 | - | - | - | - | - |
Net Cash (Debt) | 31,497 | 51,150 | 46,789 | 60,509 | 61,914 | 63,486 |
Net Cash Growth | -41.22% | 9.32% | -22.67% | -2.27% | -2.48% | 3.58% |
Net Cash Per Share | 888.49 | 1442.84 | 1304.66 | 1628.34 | 1624.95 | 1643.31 |
Filing Date Shares Outstanding | 35.45 | 35.45 | 35.45 | 36.53 | 37.57 | 38.27 |
Total Common Shares Outstanding | 35.45 | 35.45 | 35.45 | 36.53 | 37.57 | 38.27 |
Working Capital | 90,462 | 94,767 | 90,589 | 90,121 | 91,592 | 90,083 |
Book Value Per Share | 3876.74 | 3686.66 | 3609.61 | 3470.15 | 3424.20 | 3317.90 |
Tangible Book Value | 136,234 | 129,774 | 127,245 | 125,977 | 127,933 | 126,328 |
Tangible Book Value Per Share | 3843.00 | 3660.71 | 3589.27 | 3448.33 | 3405.23 | 3301.02 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.